Abbott Laboratories Extends Change in Control Agreements to December 31, 2028
Is Abbott Laboratories (ABT) Undervalued On New Device And Test Launches?
Warren Buffett Says His Favorite Holding Period Is Forever. A Secretary Who Paid $180 for 3 Shares in 1935 and Never Sold Died Worth $7 Million. Here’s What Her Rule Does for $600,000 in One Stock Today
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?
Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?
New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
What Are Wall Street Analysts' Target Price for Abbott Stock?
Does FDA Device Approval Change The Bull Case For Abbott (ABT)?
Are You Overpaying For Abbott Stock Versus Its Rivals?
Abbott Laboratories (ABT) Posted Positive Trial Results For Two Heart Devices
Abbott’s Amulet 360 demonstrates strong one-year outcomes in AFib patients
Abbott Touts Favorable Outcomes In Cardiovascular Device Trials
Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansion
Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
Abbott starts pivotal trial for mitral valve replacement device
Abbott Announces One-Year Results For Its Amulet 360 Left Atrial Appendage Occluder From The VERITAS Study; Data Show Meaningful Closure Rates Of Left Atrial Appendage And A Low Incidence Of Stroke In People With Atrial Fibrillation Not Caused By A Heart Valve Issue
Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
Can Abbott Laboratories (ABT) Stay Reasonable As Its Breakup Nears?
Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.